Mehmet An Sendur

31PUBLICATIONS
242CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Aug 13, 2026
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

|Mar 19, 2026
Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors.

Mustafa Gürbüz, Deniz Tural, Timuçin Çil

|Jan 28, 2026
Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study.

İlker Nihat Ökten, Tuba Baydaş, Mahmut Emre Yıldırım

|Jan 27, 2026
Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC.

Ebru Özgür, Ayça Çırçır, Begüm Şen Doğan

Pageof 6

Frequent Collaborators

7 joint publications

Furkan Ceylan

6 joint publications

Nuri Karadurmuş

6 joint publications

Ateş Kutay Tenekeci

4 joint publications

Safa Can Efil